The Technical Analyst
Kymera Therapeutics, Inc. [KYMR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kymera Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-6.82% $32.81
America/New_York / 25 apr 2024 @ 11:36
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 005.07 mill |
| EPS: | -2.52 |
| P/E: | -13.02 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 61.11 mill |
| Avg Daily Volume: | 0.641 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -13.02 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.21x |
| Company: PE -13.02 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-27.72 (-184.49%) $-60.53 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 31.14 - 34.96 ( +/- 5.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Baker Bros. Advisors Lp | Buy | 32 000 | Non-Qualified Stock Option (right to buy) |
| 2024-03-28 | Baker Bros. Advisors Lp | Buy | 0 | Common Stock |
| 2024-03-28 | Baker Bros. Advisors Lp | Buy | 0 | Common Stock |
| 2024-03-28 | Baker Bros. Advisors Lp | Buy | 7 379 066 | Prefunded Warrants |
| 2024-03-14 | Booth Bruce | Sell | 34 473 | Common Stock |
| INSIDER POWER |
|---|
| 44.26 |
| Last 97 transactions |
| Buy: 2 823 290 | Sell: 1 008 904 |
Forecast:
13:15 - $32.75
Live Trading Signals (every 1 min)
Forecast
1: 11:45 - $32.80
Forecast 2: 12:35 - $32.81
Forecast 3: 13:15 - $32.75
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $32.81 (-6.82% ) |
| Volume | 0.158 mill |
| Avg. Vol. | 0.641 mill |
| % of Avg. Vol | 24.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KYMR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $33.94 | N/A | Active |
|---|
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-04-25 07:00:00 - Press Release
Kymera Therapeutics To Report First Quarter 2024 Financial Results On May 2
Watertown, mass., april 25, 2024 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (tpd), will report first quarter 2024 financial results on may 2, 2024, and will host a conference call at 8:30 a.m. et.
2024-04-08 07:00:00 - Press Release
Kymera Therapeutics Announces Scientific Presentations At The American Association For Cancer Research 2024 Annual Meeting
New preclinical data on novel e3 pairing and structural mechanisms for kt-333, a first-in-class stat3 degrader, presented in aacr's late-breaking poster session
2024-03-08 10:00:00 - Press Release
Kymera Therapeutics Presents Preclinical Data For Stat6 And Tyk2 First-in-class, Oral Degrader Immunology Programs At The American Academy Of Dermatology Annual Meeting
Kt-621 (stat6) and kt-294 (tyk2) have the potential to provide biologics-like activity with oral small molecule profiles
2024-02-28 07:00:00 - Press Release
Kymera Therapeutics To Participate In Upcoming March Investor Conferences
Watertown, mass., feb. 28, 2024 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (tpd), today announced that the company will participate in fireside chats at the following upcoming investor events:
2024-02-22 07:00:00 - Press Release
Kymera Therapeutics Announces Fourth Quarter And Full Year 2023 Financial Results And Provides A Business Update
Kt-474/sar444656 (irak4) phase 2 program advancing in hs and ad with data expected in first half of 2025 kt-621 (stat6) expected to start phase 1 in second half of 2024 and kt-294 (tyk2) expected to start phase 1 in first half of 2025, both with phase 1 data in 2025 additional kt-333 (stat3) and kt-253 (mdm2) phase 1 data expected in 2024 well-capitalized with $745 million 1 in cash as of january 9, 2024, and runway into the first half of 2027 company to hold call and webcast today at 8:30 a.m. et watertown, mass.
Latest News
2024-02-28 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
2024-02-15 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.
2024-01-31 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.
2024-01-02 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2024.
2023-12-08 12:48:49 - Zacks Investment Research
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
2023-11-14 17:49:00 - Market Watch
Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian
Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.
2023-11-12 02:27:10 - Seeking Alpha
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest and cautious institutional and insider activities reflecting investor skepticism.
2023-11-04 13:10:18 - Seeking Alpha
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B.
2023-11-01 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events:
2023-10-26 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day.